NuRapid-CRISPR Rapid Pathogen Detection Technology: Adjusting early-stage treatment based on NuRapid-CRISPR results.
Traditional pathogen culture: Primarily based on traditional cultivation methods or empirical treatment.
Study summary
This study is a prospective, multicenter, integrated trial designed to evaluate, from the perspectives of diagnostic performance and clinical utility, whether a diagnostic and treatment strategy based on the NuRapid-CRISPR rapid pathogen detection technology can reduce the 28-day all-cause mortality rate in patients with sepsis or septic shock in the ICU, compared to traditional pathogen culture.
The study consists of two parts:
1. Diagnostic Accuracy Study: For all enrolled sepsis patients, microbiological specimens will undergo concurrent blinded testing, with NuRapid-CRISPR serving as the test of interest and traditional pathogen culture as the reference standard. A prospective comparison will evaluate differences between the two methods in key metrics such as pathogen detection rate, sensitivity, specificity, and turnaround time.
2. Clinical Utility Cohort Study: All patients will undergo NuRapid-CRISPR testing as part of routine clinical care. Based on whether the rapid results are adopted clinically to guide early antimicrobial therapy decisions, the cohort will naturally form an exposure group (early treatment adjustments based on NuRapid-CRISPR results) and a control group (treatment primarily based on traditional culture results or empirical therapy). The study will prospectively compare the two groups in terms of the time to optimize antimicrobial therapy, coverage of the initial treatment spectrum, and infection-related clinical outcomes.
Eligibility
Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Age ≥ 18 years, length of stay in the ICU ≤ 24 hours;
* Meets the Sepsis-3.0 diagnostic criteria (an increase in SOFA score of ≥2 points from baseline, and evidence of infection);
* Clinically suspected sepsis or septic shock; the pathogen is unknown; the clinical plan is to collect sterile or suitable specimens, such as blood, respiratory specimens, cerebrospinal fluid, and ascites, for microbiological testing;
* Expected ICU stay of ≥48 hours and ability to complete at least 28 days of clinical follow-up;
* A written informed consent form signed by the patient or their legally authorized representative;
Exclusion Criteria:
* At the time of admission, the patient had already received a definitive pathogen diagnosis (based on microbiological culture, reliable molecular testing, or serological evidence), and targeted antimicrobial therapy against that pathogen had been initiated for more than 48 hours;
* Vital signs are extremely unstable; death is expected within 24 hours;
* Patients with severe primary immunodeficiency (e.g., AIDS, active hematologic malignancies, post-transplantation of solid organs or hematopoietic stem cells, or long-term use of high-dose glucocorticoids \[prednisone ≥ 20 mg/day or equivalent dose for more than 4 weeks\] or other potent immunosuppressants);
* Women who are pregnant or breastfeeding;
* The patient or their authorized representative has expressly refused to undergo any pathogen testing;
* It is not possible to obtain a suitable specimen for testing due to anatomical, physiological, or technical reasons;
* The patient is currently participating in another interventional clinical trial that may interfere with the assessment of the primary outcome of this study;
* The patient or their authorized representative has declined to participate in this study;
Primary outcome measure(s)
28-day all-cause mortality rate — From the date of randomization through Day 28 (±2 days) Death from any cause occurring between the date of randomization and day 28 (±2 days).In-hospital deaths: Recorded in real time through daily medical record reviews. Out-of-hospital deaths: Confirmed via a structured telephone follow-up conducted on Day 28 of enrollment. The telephone follow-up will use a standardized questionnaire and will be conducted by trained study coordinators.
Trial sites (3)
Facility
City
Region
Status
Center for Critical Care Medicine, Tongji Hospital, Shanghai
Shanghai
China
Shanghai Dongfang Hospital
Shanghai
China
Yangpu District Central Hospital, Shanghai
Shanghai
China
More Shanghai 10th People's Hospital trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.